Harvey ras (HRAS) mutations in head and neck cancer (HNC) and dependence on PI3K signaling and resistance to EGFR inhibition.
Katharina Endhardt
No relevant relationships to disclose
Arun Khattri
No relevant relationships to disclose
Michaela K. Keck
No relevant relationships to disclose
Zhixiang Zuo
No relevant relationships to disclose
Damian Rieke
No relevant relationships to disclose
Anna Lena Ress
No relevant relationships to disclose
Johannes Braegelmann
No relevant relationships to disclose
Kelley Leung
No relevant relationships to disclose
Derya Mahmutoglu
No relevant relationships to disclose
Everett E. Vokes
No relevant relationships to disclose
Tanguy Y. Seiwert
Consultant or Advisory Role - Bayer/Onyx; Boehringer Ingelheim
Research Funding - Boehringer Ingelheim; Genentech; Novartis